The simple moving average for the last 20 days is -12.80% for KAPA stock, with a simple moving average of -12.80% for the last 200 days.
Is It Worth Investing in Kairos Pharma Ltd. (AMEX: KAPA) Right Now?
On September 25, 2024, KAPA’s average trading volume was 223.32K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
KAPA) stock’s latest price update
The stock of Kairos Pharma Ltd. (AMEX: KAPA) has increased by 0.50 when compared to last closing price of 2.00. Despite this, the company has experienced a -18.29% fall in its stock price over the last five trading sessions. globenewswire.com reported 2024-09-24 that LOS ANGELES, Sept. 24, 2024 (GLOBE NEWSWIRE) — Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces a groundbreaking collaboration with PreCheck Health Services Inc., a CLIA-certified and CAP-accredited clinical laboratory specializing in genetic sequencing. The partnership focuses on the development of companion biomarkers for Kairos Pharma’s cancer therapy, ENV105, which targets prostate and lung cancers. This strategic agreement aims to advance the precision of patient screening and therapy monitoring for Kairos Pharma’s Phase 1 and Phase 2 clinical trials, with the aim of advancing cancer treatment by identifying patients who will benefit most from ENV105.
KAPA Trading at -12.80% from the 50-Day Moving Average
After a stumble in the market that brought KAPA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -49.75% of loss for the given period.
During the last 5 trading sessions, KAPA fell by -18.29%, in comparison to the 20-day moving average. In addition, Kairos Pharma Ltd. saw -22.69% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for KAPA
The liquidity ratio also appears to be rather interesting for investors as it stands at 0.01.
Conclusion
To wrap up, the performance of Kairos Pharma Ltd. (KAPA) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
